[HTML][HTML] Antiplatelet therapy after percutaneous coronary intervention
Antiplatelet therapy is key to reducing local thrombotic complications and systemic
ischaemic events among patients undergoing percutaneous coronary interventions (PCI) …
ischaemic events among patients undergoing percutaneous coronary interventions (PCI) …
Antithrombotic therapy for atherosclerotic cardiovascular disease risk mitigation in patients with coronary artery disease and diabetes mellitus
D Capodanno, DJ Angiolillo - Circulation, 2020 - Am Heart Assoc
Patients with diabetes mellitus (DM) are characterized by enhanced thrombotic risk
attributed to multiple mechanisms including hyperreactive platelets, hypercoagulable status …
attributed to multiple mechanisms including hyperreactive platelets, hypercoagulable status …
[HTML][HTML] Chitosan-Based Scaffolds for the Treatment of Myocardial Infarction: A Systematic Review
B Beleño Acosta, RC Advincula, CD Grande-Tovar - Molecules, 2023 - mdpi.com
Cardiovascular diseases (CVD), such as myocardial infarction (MI), constitute one of the
world's leading causes of annual deaths. This cardiomyopathy generates a tissue scar with …
world's leading causes of annual deaths. This cardiomyopathy generates a tissue scar with …
Ticagrelor with or without aspirin in high-risk patients with diabetes mellitus undergoing percutaneous coronary intervention
Background P2Y12 inhibitor monotherapy with ticagrelor after a brief period of dual
antiplatelet therapy can reduce bleeding without increasing ischemic harm after …
antiplatelet therapy can reduce bleeding without increasing ischemic harm after …
[HTML][HTML] Protease-activated receptors and glycoprotein VI cooperatively drive the platelet component in thromboelastography
T Rudran, S Antoniak, MJ Flick, MH Ginsberg… - Journal of Thrombosis …, 2023 - Elsevier
Background Thromboelastography (TEG) is used for real-time determination of hemostatic
status in patients with acute risk of bleeding. Thrombin is thought to drive clotting in TEG …
status in patients with acute risk of bleeding. Thrombin is thought to drive clotting in TEG …
Safety and efficacy of P2Y12 inhibitor monotherapy in patients undergoing percutaneous coronary interventions
Introduction: Antiplatelet therapy represents a key strategy for the prevention of thrombotic
complications in patients with both acute and chronic coronary syndromes, particularly those …
complications in patients with both acute and chronic coronary syndromes, particularly those …
Impact of age on the safety and efficacy of ticagrelor monotherapy in patients undergoing PCI
Objectives The aim of this study was to assess the impact of age on the safety and efficacy of
ticagrelor monotherapy after percutaneous coronary intervention (PCI). Background As the …
ticagrelor monotherapy after percutaneous coronary intervention (PCI). Background As the …
Clinically driven revascularization in high-risk patients treated with ticagrelor monotherapy after PCI: insights from the randomized TWILIGHT trial
Repeat coronary revascularization is a common adverse event after successful
percutaneous coronary intervention. This analysis aimed to assess the effects of ticagrelor …
percutaneous coronary intervention. This analysis aimed to assess the effects of ticagrelor …
Platelet P2Y12 inhibiting therapy in adjunct to vascular dose of rivaroxaban or aspirin: a pharmacodynamic study of dual pathway inhibition vs. dual antiplatelet …
Aims Dual pathway inhibition (DPI) by adding a vascular dose of rivaroxaban to a single
antiplatelet agent has emerged as a promising antithrombotic strategy. However, in most …
antiplatelet agent has emerged as a promising antithrombotic strategy. However, in most …
Pharmacodynamic profiles of dual-pathway inhibition with or without clopidogrel versus dual antiplatelet therapy in patients with atherosclerotic disease
Aim Inhibition of thrombin-mediated signaling processes using a vascular dose of
rivaroxaban in adjunct to antiplatelet therapy, known as dual-pathway inhibition (DPI) …
rivaroxaban in adjunct to antiplatelet therapy, known as dual-pathway inhibition (DPI) …